AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Arvinas Inc. (ARVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

18.74

0.43 (2.35%)

At close: Feb 18, 2025, 3:59 PM

18.79

0.27%

After-hours: Feb 18, 2025, 07:12 PM EST

undefined% (undefined)

Bid	18.5
Market Cap	1.29B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.77
PE Ratio (ttm)	-6.77
Forward PE	n/a
Analyst	Buy

Ask	20.5
Volume	1,450,009
Avg. Volume (20D)	923,169
Open	18.41
Previous Close	18.31
Day's Range	18.40 - 20.38
52-Week Range	16.61 - 51.99
Beta	undefined

About ARVN

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 27, 2018

Employees 430

Stock Exchange NASDAQ

Ticker Symbol ARVN

Website https://www.arvinas.com

Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is $57, which is an increase of 204.16% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Arvinas Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-6.8%

Arvinas shares are trading lower after the company... Unlock content with Pro Subscription

3 months ago

+0.58%

Arvinas shares are trading higher after the company reported better-than-expected Q3 EPS results.

News

5 days ago · zacks.com

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 days ago · zacks.com

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

6 days ago · benzinga.com

These Analysts Revise Their Forecasts On Arvinas After Q4 Results

Arvinas, Inc. ARVN reported worse-than-expected fourth-quarter sales results on Tuesday.

1 week ago · seekingalpha.com

Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript

Arvinas, Inc. (NASDAQ:ARVN ) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Exe...

1 week ago · zacks.com

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $2.53 per share a year ago.

2 weeks ago · accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] ...

4 weeks ago · fool.com

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopha...